Calcitonin/CALCA 蛋白, Human (HEK293, Fc)

Calcitonin/CALCA Protein (Human), a member of calcitonin-like protein family, is a peptide hormone secreted by parafollicular cells (C cells) of the thyroid (endostyle). Calcitonin/CALCA Protein (Human) reduces blood calcium Ca²⁺ and inhibits the effects of parathyroid hormone (PTH), which is used an antagonist against PTH and Vitamin D3a. Calcitonin/CALCA Protein (Human) has been used widely for research of bone disorders such as osteoporosis, hypercalcemia, and Paget’s disease. Calcitonin/CALCA Protein, Human (HEK293, Fc) is a recombinant protein with a Fc label that consists of 141amino acids and is expressed in HEK293^{[1][2][3][4][5]}.

降钙素由 CALCA 基因编码，通过促进这些离子与骨骼的结合，导致血钙和磷酸盐水平快速而短暂地降低。这种激素在钙稳态中发挥着至关重要的作用，作为一种反调节机制来维持血液中平衡的矿物质水平。此外，katacalcin (一种源自 CALCA 基因的肽) 被认为是一种有效的血浆钙降低因子。降钙素调节骨吸收和调节循环矿物质浓度的能力强调了其在骨骼健康和全身矿物质平衡中的重要性。进一步探索参与这些作用的分子途径可能有助于更深入地了解降钙素在与钙代谢异常相关的疾病中的作用和潜在的治疗应用^[1]。
Calcitonin/CALCA 蛋白 (Human) 通过抑制骨骼中的破骨细胞活性和抑制肾小管细胞对 Ca²⁺ 和磷酸盐的重吸收来降低血液中的 Ca²⁺ 水平，导致明显的低钙血症^[3]。
Calcitonin/CALCA 蛋白 (Human) 通过直接抑制骨吸收以及在钙动员期间通过抑制垂体腺释放泌乳素的间接作用，保护骨骼免受钙的流失，从而实现骨骼保护的作用^[6,7]。
Calcitonin/CALCA 蛋白 (Human) 主要通过抑制破骨细胞来降低血钙和磷酸盐，并防止由于吸收 Ca²⁺ 而导致的餐后高钙血症^[8]。

Calcitonin/CALCA Protein (Human) (10 nM, 8 天) 能够抑制由 PTH 刺激的钙释放和骨骼的基础 ⁴⁵Ca 释放^[3]。
Calcitonin/CALCA Protein (Human) (0.01-10000 nM，48 小时) 以剂量依赖性的方式抑制 PTH (10 nM) 刺激的骨重吸收^[5]。

在甲状旁腺激素 (PTH) 高钙血症期间，甲状腺完整 (CT+) 大鼠的 Calcitonin/CALCA 蛋白 (Human) 水平明显高于甲状腺切除 (CT-) 对照组^[4]。

Human

HEK293

C-hFc

P01258 (A26-N141)

796  [NCBI]

40-48 kDa

• 
  Greater than 95% as determined by Tris-Bis PAGE.

无菌粉末.

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4 or 20 mM PB, 150 mM NaCl, pH 7.4. Normally 5% trehalose is added as protectant before lyophilization.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Sekiguchi T, et al. Evidence for Conservation of the Calcitonin Superfamily and Activity-regulating Mechanisms in the Basal Chordate Branchiostoma floridae: INSIGHTS INTO THE MOLECULAR AND FUNCTIONAL EVOLUTION IN CHORDATES. J Biol Chem. 2016 Jan 29;291(5):2345-56.  [Content Brief]

  [2]. Xie J, et al. Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations. Int J Endocrinol. 2020 Sep 10;2020:3236828.  [Content Brief]

  [3]. Carney SL. Calcitonin and human renal calcium and electrolyte transport. Miner Electrolyte Metab. 1997;23(1):43-7.  [Content Brief]

  [4]. Rodriguez M, et al. Calcitonin, an important factor in the calcemic response to parathyroid hormone in the rat. Kidney Int. 1991 Aug;40(2):219-25.  [Content Brief]

  [5]. Yamamoto I, et al. Human calcitonin gene-related peptide possesses weak inhibitory potency of bone resorption in vitro. Calcif Tissue Int. 1986 Jun;38(6):339-41.  [Content Brief]

  [6]. Horwitz MJ,et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res. 2005 Oct;20(10):1792-803.  [Content Brief]

  [7]. Woodrow JP, et al. Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. Endocrinology. 2006 Sep;147(9):4010-21.  [Content Brief]

  [8]. Inzerillo AM, et al. Calcitonin: physiological actions and clinical applications. J Pediatr Endocrinol Metab. 2004 Jul;17(7):931-40.  [Content Brief]